| Page 19 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Winter Patient and Family Virtual Conference, November 13, 2021

Event Date: 
Sat, 11/13/2021 - 8:00am (EST)
Conference Event Type: 

Fall Patient and Family Virtual Conference, September 11, 2021

Sessions

Understanding Low Risk MDS 2021 Fall Patient Family Conference
  Suresh Balasubramian, MD, Karmanos Cancer Center

Understanding Aplastic Anemia 2021 Fall Patient Family Conference
  Daria Babushok, MD, PhD, Penn Medicine

Event Date: 
Sat, 09/11/2021 - 8:00am (EDT)
Conference Event Type: 

Summer Patient and Family Virtual Conference, July 17, 2021

Sessions

Managing the Side Effects of Bone Marrow Failure - Summer 2021 Conference
 Eric Padron, MD, Moffitt Cancer Center

Diagnosing Bone Marrow Failure Diseases - Summer 2021 Conference
 Amy Duffield, MD, PhD, Memorial Sloan Kettering

Event Date: 
Sat, 07/17/2021 - 8:00am (EDT)
Conference Event Type: 

Aplastic Anemia, Myelodysplastic Syndromes, and Myeloproliferative Neoplasms: The 8th (Virtual) Patient Conference, June 26, 2021

Sessions

8th Seattle Patient Conference: Ask an Expert
 H. Joachim Deeg, MD

8th Seattle Patient Conference - Living Well with MDS/MPN
 Krisstina Gowin, DO, University of Arizona

Event Date: 
Sat, 06/26/2021 - 8:00am (EDT)
Conference Event Type: 

Spring Patient and Family Virtual Conference, April 10, 2021

Event Date: 
Sat, 04/10/2021 - 8:00am (EDT)
Conference Event Type: 

Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]). 

FDA Approves First Treatment for Common Type of Post-Transplant Infection that is Resistant to Other Drugs

For Immediate Release:
November 23, 2021

 

Today, the U.S. Food and Drug Administration approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients (12 years of age and older and weighing at least 35 kilograms) with post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV. Livtencity works by preventing the activity of human cytomegalovirus enzyme pUL97, thus blocking virus replication.

Blood and marrow transplants (BMT) help people with advanced myelodysplastic syndromes (MDS)

Not enough people have access to life-saving transplant

Although BMT is the only known cure for MDS, many people aren’t aware of BMT or think that they’re too old to have one because of its side effects. 

Using smaller doses of therapy with BMT have made it safer. Now a new study of 400 older adults, aged 50 to 75, suggests that this type of BMT, along with a matched donor, helps people with advanced MDS live longer with a similar quality of life.

(Please follow link above for complete article)